Mebo AG

Mebo AG. Mebo AG is a Swiss-based biotechnology and pharmaceutical company specializing in regenerative medicine, most notably for the treatment of burns and wounds. Founded by Chinese surgeon and researcher Xu Rongxiang, the company is best known for developing the Moist Exposed Burn Ointment (MEBO) and pioneering the "Moist Exposed Burn Therapy" (MEBT) protocol. With its headquarters in Zug, a major center for commodity trading, Mebo AG operates globally, conducting extensive clinical research and holding numerous international patents for its technologies.

History

The company's origins are rooted in the work of its founder, Xu Rongxiang, who began his research into burn treatment in the 1980s in Beijing. His development of the Moist Exposed Burn Ointment led to the formal establishment of Mebo International in 1990. The corporate structure was later reorganized, with Mebo AG incorporated in Switzerland to serve as the global holding and research entity. A significant early milestone was the company's involvement in relief efforts following the 1999 İzmit earthquake in Turkey, where its products were used extensively. Throughout the 2000s, Mebo AG expanded its presence, establishing subsidiaries and research collaborations in the United States, the Middle East, and Southeast Asia, often working with local health ministries and hospitals.

Products and services

The flagship product of Mebo AG is the Moist Exposed Burn Ointment (MEBO), a topical formulation designed to create a moist microenvironment for wound healing. This product is the core component of the company's proprietary Moist Exposed Burn Therapy (MEBT) system. Beyond burn care, the company's portfolio has expanded to include a range of dermatological preparations for conditions like psoriasis and diabetic ulcers. Mebo AG also provides specialized training and certification programs for medical professionals on the MEBT protocol, often in partnership with institutions like the World Health Organization and various national Red Cross societies. These services are supported by a global distribution network managed from its Zug headquarters.

Research and development

Research and development at Mebo AG is intensely focused on the science of organ regeneration and tissue engineering. The company operates dedicated R&D facilities, including the Mebo Research Center in Beijing. A central pillar of its research is the "Regenerative Restorative Therapy" (RRT) concept, which aims to activate latent stem cells *in situ*. This work has led to numerous peer-reviewed publications in journals such as *Burns* and the *Journal of Trauma*. The company holds an extensive international patent portfolio covering its formulations and methodologies, with particular strength in jurisdictions like the USPTO and the European Patent Office. Collaborative projects have been undertaken with universities, including Harvard University and Tsinghua University.

Corporate affairs

Mebo AG maintains a decentralized corporate structure, with its strategic and financial operations directed from its Zug headquarters in the Canton of Zug. The company is privately held, with Xu Rongxiang serving as the controlling shareholder and Chairman. Key subsidiaries, such as Mebo International, Inc. in the United States, handle regional marketing, sales, and further clinical work. The company engages in significant philanthropy, primarily through the China National Health Development Research Center and disaster relief initiatives, donating products and medical teams to events like the 2004 Indian Ocean tsunami. Its corporate governance emphasizes direct involvement from its founder in all major scientific and strategic decisions.

Legal and regulatory issues

Mebo AG has navigated a complex international regulatory landscape. Its products, classified as biologics in some markets and cosmeceuticals in others, have undergone regulatory review by bodies including the Food and Drug Administration (FDA) in the United States and the Therapeutic Goods Administration in Australia. The company has been involved in several intellectual property disputes to defend its patents and trademarks related to the MEBO name and formulation. Furthermore, it has faced periodic scrutiny from segments of the conventional medical community regarding the evidence base for its therapies, leading to ongoing clinical studies designed to meet evidence-based medicine standards set by agencies like the European Medicines Agency (EMA).